ReviewMolecular biotechnology2026
A Comprehensive Bibliometric and Visual Analysis of EGR1 in Cardiovascular Disease.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Early Growth Response 1 (EGR1) is a crucial transcription factor that regulates diverse cellular processes, including growth, differentiation, proliferation, inflammation, apoptosis, and autophagy. It plays a vital role in maintaining cardiac homeostasis and is deeply implicated in the pathological mechanisms leading to cardiomyocyte death, making it a promising therapeutic target for cardiovascular diseases. To better understand the research landscape of EGR1 in this context, we conducted a bibliometric analysis using data from the Web of Science Core Collection (WoSCC) covering the period from 2014 to 2024, retrieved on 31 December 2024. A total of 2,112 publications related to EGR1 were identified, of which 173 specifically addressed cardiovascular disease and were published across 126 journals. Global research output on this topic has shown fluctuating growth over the past decade, with China contributing the most publications and citations. The Institut national de la santé et de la recherche médicale (Inserm) emerged as the most productive institution. Zhang Y authored the highest number of papers, while Wang J received the most citations. Scientific Reports was the most prolific journal, whereas the Journal of Biological Chemistry was the most influential in terms of citation metrics. Keyword co-occurrence and cluster analysis revealed major research themes such as apoptosis, inflammation, oxidative stress, angiogenesis, and autophagy. These findings provide a comprehensive overview of EGR1-related cardiovascular research and offer a valuable reference for future investigations into its mechanisms and therapeutic potential.
Indexed as
Identifiers
40880050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.